• Wondering if DaVita at US$150.05 is priced for its future potential or already reflecting it? This article breaks down what that current tag might really mean for you.
• The stock has seen mixed moves recently, with a 3.1% return over 7 days, a 0.4% decline over 30 days, a 31.0% return year to date, and a 3.5% decline over the last year, which may signal shifting views on both opportunity and risk.
• Recent news coverage has focused on DaVita's role within the broader healthcare sector and how changing expectations around patient volumes and treatment demand could affect business stability. There has also been ongoing discussion about regulatory oversight for healthcare providers, which can influence how investors think about risk.
• On Simply Wall St's valuation checks, DaVita holds a value score of 5/6, which raises some clear questions about where the price sits relative to estimated worth. The next sections will unpack the main valuation approaches before finishing with a framework that can help you go a step further in judging value for yourself.

DaVita delivered -3.5% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Approach 1: DaVita Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s value to estimate what the business might be worth right now.

For DaVita, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $1.29b. Simply Wall St uses analyst estimates through 2026, with projected Free Cash Flow of $1.24b in 2026, and then extends those forecasts out to 2035 using its own assumptions.

These yearly cash flows, such as the discounted values of $1,155.54m in 2026 and $698.20m in 2035, are added together and adjusted for the second stage of the model to arrive at an estimated intrinsic value of $386.99 per share. Compared with the recent share price of $150.05, the DCF output suggests the stock is 61.2% undervalued based on these inputs and assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests DaVita is undervalued by 61.2%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for DaVita.

Approach 2: DaVita Price vs Earnings

P/E is a common way to value profitable companies because it links what you are paying directly to the earnings the business is generating today. A higher or lower P/E typically reflects what the market expects for future growth and how much risk investors feel they are taking on, so a “normal” or “fair” P/E tends to rise with stronger growth and fall when risks look higher.

DaVita currently trades on a P/E of 13.88x, compared with the Healthcare industry average of 22.03x and a peer average of 38.24x. Simply Wall St’s Fair Ratio for DaVita is 23.08x. This is its proprietary view of what a reasonable P/E could be after factoring in elements such as the company’s earnings growth profile, profit margins, industry, market cap and specific risks.

This Fair Ratio can be more informative than a simple peer or sector comparison because it adjusts for those company specific characteristics rather than assuming all healthcare names deserve the same multiple. Set against the current P/E of 13.88x, the Fair Ratio of 23.08x indicates that, on this measure, DaVita’s shares are trading below that modeled “fair” level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your DaVita Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a simple way for you to write the story you believe about DaVita, link that story to specific assumptions for future revenue, earnings and margins, and see how those assumptions translate into a Fair Value that you can compare with the current share price on Simply Wall St’s Community page. Narratives are updated when new news or earnings arrive. One investor might lean toward a more cautious DaVita view closer to the US$126 Fair Value, another might see a stronger case around US$179.66, and you can quickly see which story your own view fits and how that lines up against today’s US$150.05 price.

For DaVita, however, we will make it really easy for you with previews of two leading DaVita Narratives:

🐂 DaVita Bull Case

Fair value in this bullish narrative: US$151.71 per share.

At a last close of US$150.05, this narrative implies DaVita is about 1.1% below its fair value.

Revenue growth underpinning this view: 3.6% a year.

• Analysts in this camp see steady revenue growth and a modest lift in profit margins, supported by cost control, technology, and clinical work aimed at better outcomes over time.
• They factor in ongoing share buybacks, which reduce the share count and feed into higher earnings per share if earnings hold up.
• The fair value range, from US$126 on the cautious side to US$190 on the optimistic side, reflects different views on how much earnings and valuation multiples can support the current business model.

🐻 DaVita Bear Case

Fair value in this bearish narrative: US$126.00 per share.

At a last close of US$150.05, this narrative implies DaVita is about 19.1% above its fair value.

Revenue growth underpinning this view: 4.8% a year.

• This group of analysts still expects revenue growth but bakes in lower profit margins over time, with higher G&A and IT costs and slower benefits from new clinical tools weighing on earnings.
• They flag pressure points like treatment volume sensitivity to external events, payer mix uncertainty, and ongoing losses in Integrated Kidney Care as key reasons to be cautious.
• In this view, the assumed fair value of US$126.00 builds in both margin pressure and the risk that large investments and clinical projects take longer than expected to translate into stronger earnings.

Seen together, these narratives show how different assumptions on margins, buybacks, and execution can move DaVita's fair value band quite a long way. It is therefore worth deciding which story feels closer to your own expectations before acting on the current US$150.05 price. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for DaVita on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for DaVita? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.